Analyst Price Target is $6.90
▲ +389.36% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Gemini Therapeutics in the last 3 months. The average price target is $6.90, with a high forecast of $18.00 and a low forecast of $1.50. The average price target represents a 389.36% upside from the last price of $1.41.
Current Consensus is
The current consensus among 5 contributing investment analysts is to hold stock in Gemini Therapeutics. This rating has held steady since November 2021, when it changed from a Buy consensus rating.
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.